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Albert W Lee1 and Susan S Cho2*Abstract
The objective of this study was to estimate the independent associations between intake of phosphorus (P) and
bone health parameters such as bone mineral content (BMC) and bone mineral density (BMD). It provides odds
ratio (OR) of osteoporosis with quartiles of P intake adjusted for covariates (i.e., age, gender, BMI, and consumption
of calcium (Ca), protein, total dairy foods, and vitamin D as well as intakes of supplemental Ca, vitamin D, and
multivitamins/minerals). Data came from males and females aged 13–99 years who participated in the 2005–2010
National Health and Nutrition Examination Survey (NHANES). Analyses showed that higher P intake was associated
with higher Ca intake, and that dietary Ca:P ratios (0.51-0.62, with a mean of 0.60 for adults) were adequate in all
age/gender groups. High intake of P was positively associated with BMC in female teenagers (Q4 vs. Q1: BMC,
30.9 ± 1.1 vs. 29.0 ± 0.5 g, P = 0.001). It was also positively associated with BMC and BMD as well as reduced risk of
osteoporosis in adults >20 years of age (Q4 vs. Q1: OR of osteoporosis, 0.55; 95% confidence interval [CI], 0.39- 0.79;
P = 0.001; BMC, 37.5 ± 0.4 vs. 36.70 ± 0.3 g, P < 0.01; BMD, 0.986 ± 0.004 vs. 0.966 ± 0.005 g/cm2, P < 0.05). The
data suggest that high intake of P has no adverse effect on bone metabolism in populations with adequate Ca
intake, and that it is also associated with positive bone parameters in some age/gender groups.
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Maintenance of healthy bones throughout the lifespan is
physiologically beneficial. Greater bone formation and/or
less bone resorption lead to an increase in BMC and/or
BMD. Assessment of BMD is used to define osteoporosis,
a systemic skeletal disease characterized by low BMD and
abnormal bone micro-architecture. These deficits lead to
fragility and increased susceptibility to fractures [1]. BMC
and BMD are considered good biomarkers for bone health
[2]. The main factors that affect maximum bone mass and
strength are genetic predisposition and dietary habits [3].
Dietary interventions (e.g., Ca supplementation) increase
BMD or limit loss of it in older adults and postmeno-
pausal females, reducing the risk of osteoporotic fractures.
The effects of high P intake on bone parameters have
been controversial. Many studies report that high P in-
take is harmful to bone health in subjects whose dietary
Ca:P ratio is extremely low [4-10]. However, there is
strong evidence that high P intake has no negative* Correspondence: susanscho1@yahoo.com
2NutraSource, 6309 Morning Dew Ct., Clarksville, MD 21029, USA
Full list of author information is available at the end of the article
© 2015 Lee and Cho.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.impact on Ca balance in normal subjects with appropri-
ate dietary Ca and P intakes [11-15].
We hypothesized that in those with adequate Ca intake,
the adverse effects of higher P intake on bone metabolism
would be negligible. Therefore, we examined the associ-
ation between P intake and bone health parameters in a
cross-sectional cohort of the 2005–2010 NHANES.Methods
All analyses were completed using Statistical Analysis Soft-
ware (SAS) 9.2 and SUDAAN version 11 and used sampling
weights, primary sampling units and strata information pro-
vided by NHANES. Day 1 dietary, exam, lab and question-
naire data were used for NHANES 2005–2010 with
exclusions for age < 13, incomplete or unreliable data and
pregnant or lactating females. All analyses were done for
males, females and genders combined. The age groups for
the analyses were 13–19, 20–49, 50–99 and 20–99. The
Osteoporosis questionnaire (OSQ) files were used to indi-
cate presence of osteoporosis. The Prescription Medication
(RXQ) files were used to identify subjects taking osteo-
porosis or estrogen medications. The Dual Energyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(g/cm2) and BMC (g) measurements.
Phosphorus quartiles were calculated by age group and
gender using SUDAAN proc descript. Means by phosphorus
intake quartile for nutrient intakes, questionnaire responses
and lab results were calculated using SUDAAN proc re-
gress with separate regressions within age groups and gen-
der using indicator variables for the P intake quartiles.
Least Square Means (LSM) and standard errors (SE)
were calculated for total femur BMC and BMD across
the quartiles of phosphorus intake using SUDAAN proc
regress by age groups and gender. P-value statistics were
calculated for quartile trend on quartile numbers on
phosphorus intake in grams. The LSM analysis was done
after adjustments for age, gender, energy, body mass
index (BMI), protein intake, diary intake, calcium intake,
vitamin D intake and flags for supplemental intake of
calcium, vitamin D, and multi-vitamins. Flags were also
included for taking osteoporosis medication and, for fe-
males, taking estrogen medication.
Odds ratios were calculated for the indication of osteo-
porosis across the quartiles of phosphorus intake using
SUDAAN proc rlogist by age groups and genders. The
same trend statistics were calculated as in the LSM ana-
lysis. The covariate sets used were as used in the LSM
analysis except the flag for osteoporosis was not included.
The 13–19 age group was not used in this logistic analysis
since the NHANES questionnaire for osteoporosis does
not include this age group. Two flags were used as indica-
tors of osteoporosis. These were based on the prescription
medication rx_drug files and the osteoporosis question-
naire osq files. Osteoporosis was determined as indicated
if one or more of 2 conditions were satisfied: (1) Answer
yes to question “Has a doctor ever told you that you had
osteoporosis, sometimes called thin or brittle bones?” and
(2) Answer yes to question “Has a doctor ever told you
that you had broken or fractured your hip?”.
Results and discussion
The importance of Ca and P in maintaining bone health is
well established [3]. Based on Ca retention from balanceTable 1 Demographics of NHANES subjects




Total Dairy (oz equivalent) 2.1±0.05a
Soft Drinks (oz) 14.9±0.7a
Supplemental Calcium (%) 20.8±1.2a
Multivitamin use (%) 18.8±1.3a
Osteoporosis medication (%) NA
NA=not applicable. a,b,cDifferent superscripts indicate statistically significantly differestudies, factorial estimates of requirements, and data on
changes in BMD and BMC, the Institute of Medicine
(IOM) [3] set an adequate intake (AI) of calcium at
1,200 mg/day for adults >50 years of age and a Tolerable
Upper Intake Level (UL) at 2,500 mg/day. The Recom-
mended Dietary Allowances (RDA) and UL for P are 700
and 4,000 mg/day for adults, respectively, and 1,250 and
4,000 mg/day in teenagers [3].
Characteristics of the NHANES population and intakes of
P and Ca
Table 1 shows characteristics of the NHANES population.
Compared with teenagers and adults aged 20–49 years,
those aged ≥50 years took in less dietary Ca and P, soft
drinks, and dairy foods. They also used more supplemental
Ca and multivitamins. The LSM of various ethnic groups
were compared for intakes of Ca and P. Whites had the
highest intakes of both Ca and P; Blacks had the lowest
(Whites vs. Blacks: Ca, 1,013 vs. 799 mg/day, P < 0.01; P,
1,409 vs. 1,188 mg/day, P < 0.01; data not shown in tables).
Table 2 shows that high P consumers (Q4) had P in-
take two to three times higher than the RDA. It was ap-
proximately 2.4 g/day, well below the UL of 4 g/day.
None of the high P intake groups had P intake over the
UL of 4.0 g/day. Data also showed that higher P intake
was associated with higher Ca intake.
Dietary intake of Ca was approximately 1,000 mg/day,
with that among high P consumers 1.5-fold higher than
the recommended RDA (1,620-1,890 mg/day). Ca intake
was well below the UL of 2,500 mg/day [3]. None of the
high P intake groups had Ca intake over the UL of 2.5 g/
day. According to nationwide food consumption surveys,
milk was the leading source of P as well as Ca in all age
groups [16]. In all age/gender groups, NHANES data in-
dicated that the dietary Ca:P molar ratio was adequate,
with a range of 0.51-0.62. Compared with females, males
had higher intakes of Ca and P (Table 2).
Markers of bone metabolism and OR of osteoporosis
A multivariate model that included adjustments for in-









nt values from other age groups.
Table 2 Phosphorus and Calcium intakes, mg/day
Gender LSM Q1 Q2 Q3 Q4
Phosphorus intakes, mg/day
13-19 yr, All 1382±14 597±7 1037±5 1471±8 2421±39
13-19 yr, Male 1624±23a 599±15 1055±8 1476±10 2484±49
13-19 yr, Female 1138±10b 596±8 1023±6 1465±10 2247±62
20-49 yr, All 1443±6 684±6 1121±3 1541±4 2426±21
20-49 yr, Male 1701±10a 718±9 1126±6 1548±5 2487±26
20-49 yr, Female 1179±4b 671±8 1118±5 1531±6 2231±32
50-99 yr, All 1377±4 701±6 1091±3 1451±4 2260±17
50-99 yr, Male 1592±8a 698±7 1087±5 1462±5 2315±23
50-99 yr, Female 1172±4b 703±7 1094±4 1438±5 2117±22
20-99 yr, All 1368±4 667±4 1071±2 1450±3 2283±14
20-99 yr, Male 1602±7a 693±6 1075±3 1457±4 2348±19
20-99 yr, Female 1145±4b 657±5 1068±2 1441±5 2110±21
Calcium intakes according to phosphorus intake quartiles, mg/day
13-19 yr, All 1070±14 470±11 768±15 1144±20 1896±45
13-19 yr, Male 1243±23a 464±15 797±23 1114±28 1918±53
13-19 yr, Female 894.8±16b 472±14 747±17 1182±24 1833±83
20-49 yr, All 1020.5±7 496±9 791±12 1061±10 1732±25
20-49 yr, Male 1157±11a 477±14 746±19 1004±13 1742±30
20-49 yr, Female 880±8b 503±10 824±14 1137±16 1700±41
50-99 yr, All 895±6 462±9 710±8 946±13 1460±18
50-99 yr, Male 985±8a 437±11 678±11 888±11 1461±22
50-99 yr, Female 817±8b 472±10 730±11 1001±22 1460±29
20-99 yr, All 966±5 481±5 750±6 1010±8 1622±18
20-99 yr, Male 1086±8a 458±7 713±13 9529±9 1631±21
20-99 yr, Female 852±7b 490±6 775±8 1079±14 1597±27
Dietary Ca:P intake molar ratio
13-19 yr, All 0.60 0.62 0.57 0.60 0.60
13-19 yr, Male 0.59 0.59 0.59 0.60 0.58
13-19 yr, Female 0.60 0.64 0.57 0.59 0.62
20-49 yr, All 0.55 0.57 0.54 0.53 0.55
20-49 yr, Male 0.52 0.51 0.52 0.50 0.54
20-49 yr, Female 0.58 0.61 0.56 0.56 0.59
50-99 yr, All 0.55 0.56 0.54 0.54 0.54
50-99 yr, Male 0.52 0.51 0.51 0.51 0.54
50-99 yr, Female 0.57 0.58 0.57 0.57 0.57
20-99 yr, All 0.55 0.57 0.54 0.54 0.54
20-99 yr, Male 0.52 0.51 0.51 0.51 0.54
20-99 yr, Female 0.58 0.60 0.57 0.57 0.58
a,bDifferent superscripts indicate statistically significantly different values
between males and females.
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with improved bone health. This was indicated by im-
proved BMC, BMD, and/or reduced OR of osteoporosis
in some age/gender groups. In all age/gender groupswith higher Ca intake, increased P had no adverse effects
on bone health parameters. The dietary Ca:P ratio was
within the safe intake range. P intake was not associated
with serum concentrations of vitamin D or P (data not
shown). Compared with females, males had higher
values for BMC and BMD (Tables 3 and 4).
Table 3 shows quartiles of the LSM of total femur
BMC and a linear trend in P (mg). Data show a positive
association between P intake and increasing BMC
among those aged 20–99 years (3.4-4.2%; P < 0.05), in
those aged 20–49 years (4.6%; P < 0.01), and females
aged 13–19 years (6.6%; P < 0.01). Increases in P intake
were associated with significant gains in total femur
BMC. In males aged 20–49 years, there was an increas-
ing trend of BMC in response to high P intake (4.0%;
P = 0.10).
Of those aged 20–99 years, assessment by ethnic group
attenuated statistical power for differentiation. Increased P
intake was associated with higher BMC only in Whites
(Q4 vs. Q1: 37.5 vs. 36.0; P < 0.01), with an increasing
trend of BMC (Q4 vs. Q1: 38.8 vs. 37.7; P = 0.09) in Black
participants. A comparison of LSMs showed that whites
and Hispanics had significantly lower BMC than blacks,
but it was higher than the level in other ethnic groups (in-
cluding Asians).
Table 4 reports total femur BMD in each quartile.
High P intake in those aged 20–99 years was associated
with a 2.1% increase in total femur BMD. Similar in-
creases were observed in all adults and females aged 20–
49 years. In these groups, the highest quartile of P intake
produced 2.0-2.4% greater BMD compared with the low-
est quartile. In teenagers, P intake was not associated
with BMD.
When those aged 20–99 years were compared by ethni-
city, increased P intakes were associated with higher BMD
only in Whites (Q4 vs. Q1: 0.976 vs. 0.946; P < 0.01).
Whites and Hispanics had significantly lower BMD than
blacks, but levels were higher than in other ethnic groups
(including Asians). In adults aged ≥20 years, P intake was
associated with improved bone health as indicated by in-
creased BMD. In contrast, the Framingham Osteoporosis
Study [17] found that total P intake was not related to
BMD in 1,413 females and 1,125 males whose dietary Ca:
P ratios ranged from 0.60 to 0.62.
Table 5 shows the OR of osteoporosis by quartile.
Males and females aged 20–99 years with the highest
P intake had a 45% lower risk of osteoporosis (OR =
0.55; 95% CI, 0.39-0.79; P < 0.01) compared with those
who consumed the least P. When NHNANES subjects
were divided into two age groups, 20–49 and 50–99,
statistical power was attenuated. High P intake was asso-
ciated with a decreasing trend for osteoporosis. Risk re-
duction was 54% (P = 0.10) in those aged 20–49 years. In
those aged 50–99 years, it was 29% (P = 0.06).
Table 3 Femur Bone mineral content (BMC) according to P intake quartiles
Age, gender LSM Q1 Q2 Q3 Q4 P trend
13-19 yr, All 35.1±0.2 34.6±0.5 34.9±0.3 35.5±0.3 35.2±0.5 NS
13-19 yr, Male 40.1±0.3a 39.5±0.8 40.0±0.7 41.1±0.5 39.6±0.6 NS
13-19 yr, Female 29.6±0.2b 29.0±0.5 29.9±0.3 29.5±0.5 30.9±1.1 <0.01
20-49 yr, All 37.4±0.1 36.5±0.3 37.3±0.2 37.5±0.3 38.2±0.3 <0.01
20-49 yr, Male 43.8±0.2a 42.9±0.7 43.4±0.4 43.4±0.4 44.6±0.4 0.1010
20-49 yr, Female 30.6±0.1b 29.9±0.4 30.9±0.2 31.4±0.3 31.0±0.6 <0.05
50-99 yr, All 35.8±0.1 35.5±0.4 35.6±0.2 36.0±0.2 35.9±0.4 NS
50-99 yr, Male 43.6±0.3a 43.1±1.0 43.2±0.8 44.0±0.6 43.7±0.7 NS
50-99 yr, Female 28.6±0.1b 28.6±0.4 28.6±0.2 28.5±0.2 28.4±0.5 NS
20-99 yr, All 36.7±0.1 36.0±0.3 36.4±0.2 36.8±0.2 37.5±0.4 <0.01
20-99 yr, Male 43.7±0.1a 42.9±0.5 43.2±0.3 43.4±0.2 44.5±0.3 <0.05
20-99 yr, Female 29.7±0.1b 29.3±0.3 29.7±0.2 30.1±0.2 30.3±0.4 <0.05
Comparison of ethnicity; 20–99 yr, All (males and females combined)
Hispanic 35.9±0.16t 35.7±0.32 36.1±0.31 35.8±0.20 36.0±0.32 NS
White 36.9±0.14x 36.0±0.28 36.5±0.23 37.0±0.21 37.5±0.25 <0.01
Black 38.2±0.21y 37.7±0.48 37.8±0.28 38.8±0.35 38.8±0.60 0.09
Other 33.5±0.33t,z 32.9±0.67 33.4±0.56 32.8±0.36 35.3±1.01 NS
Femur BMCs were calculated for each quartile after adjustments for age, gender, kcal, BMI, intakes of calcium, protein, total dairy foods, and vitamin D, and flags
to denote supplemental calcium, supplemental vitamin D, supplemental multi vitamin/mineral and a flag to denote prescription medication for osteoporosis and
estrogen medication (females only).
a,bDifferent superscripts indicate statistically significantly different LSM values between males and females.
t, x, y, zDifferent superscripts indicate statistically significantly different LSM values in 4 ethnic groups.
Table 4 Femur Bone mineral density (BMD) according to P intake quartiles
Gender LSM Q1 Q2 Q3 Q4 P trend
13-19 yr, All 1.000±0.003 0.990±0.01 0.999±0.006 1.003±0.005 1.009±0.008 NS
13-19 yr, Male 1.038±0.005a 1.027±0.02 1.039±0.013 1.048±0.008 1.035±0.010 NS
13-19 yr, Female 0.959±0.004b 0.945±0.011 0.963±0.006 0.956±0.011 0.993±0.021 NS
20-49 yr, All 1.014±0.002 0.999±0.006 1.016±0.004 1.017±0.005 1.023±0.006 <0.05
20-49 yr, Male 1.062±0.004a 1.058±0.012 1.058±0.006 1.056±0.006 1.069±0.008 NS
20-49 yr, Female 0.964±0.003 b 0.948±0.007 0.970±0.005 0.977±0.007 0.971±0.010 <0.05
50-99 yr, All 0.924±0.002 0.919±0.006 0.923±0.005 0.927±0.004 0.926±0.007 NS
50-99 yr, Male 1.001±0.004a 0.996±0.009 1.005±0.009 1.004±0.006 0.998±0.008 NS
50-99 yr, Female 0.853±0.003b 0.858±0.008 0.849±0.006 0.852±0.006 0.852±0.011 NS
20-99 yr, All 0.976±0.002 0.966±0.005 0.973±0.004 0.977±0.004 0.986±0.004 <0.05
20-99 yr, Male 1.037±0.003a 1.034±0.008 1.036±0.005 1.029±0.004 1.044±0.005 NS
20-99 yr, Female 0.915±0.002b 0.909±0.005 0.912±0.004 0.922±0.005 0.924±0.008 NS
Comparison of ethnicity; 20–99 yr, All (males and females combined)
Hispanic 0.997±0.003t,z 0.986±0.007 1.002±0.007 1.002±0.004 0.997±0.007 NS
White 0.964±0.002t,x 0.946±0.006 0.958±0.004 0.967±0.004 0.976±0.004 <0.01
Black 1.048±0.004y 1.041±0.008 1.043±0.005 1.054±0.007 0.968±0.010 NS
Other 0.944±0.005z 0.932±0.016 0.955±0.012 0.926±0.010 0.968±0.022 NS
Femur BMDs were calculated for each quartile after adjustments for age, gender, kcal, BMI, intakes of calcium, protein, total dairy foods, and vitamin D, and flags
to denote supplemental calcium, supplemental vitamin D, supplemental multi vitamin/mineral and a flag to denote prescription medication for osteoporosis and
estrogen medication (females only).
a,bDifferent superscripts indicate statistically significantly different LSM values between males and females or among different ethnic groups.
t, x, y, zDifferent superscripts indicate statistically significantly different LSM values in 4 ethnic groups.
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Table 5 Odd ratio of osteoporosis according to P intake quartiles
Odd ratio
Gender Q1 Q2 Q3 Q4 P trenda
20-49 yr, All 1.00 0.39 (0.19, 0.78) 0.54 (0.26, 1.12) 0.46 (0.16,1.27) 0.10
20-49 yr, Male 1.00 0.36 (0.11, 1.20) 0.51 (0.16, 1.60) 0.60 (0.15, 2.38) NS
20-49 yr, Female 1.00 0.37 (0.18, 1.00) 0.73 (0.29, 1.39) 0.27 (0.06, 1.33) NS
50-99 yr, All 1.00 0.84 (0.63, 1.11) 0.77 (0.55, 1.08) 0.71(0.48, 1.04) 0.06
50-99 yr, Male 1.00 0.45 (0.23, 0.89) 0.55 (0.26, 1.15) 0.52 (0.17, 1.53) NS
50-99 yr, Female 1.00 1.01 (0.71, 1.44) 0.98 (0.61, 1.59) 1.05 (0.52, 2.09) NS
20-99 yr, All 1.00 0.76 (0.59, 0.97) 0.68 (0.51,0.91) 0.55 (0.39, 0.79) <0.001
20-99 yr, Male 1.00 0.49 (0.30, 0.80) 0.56 (0.32, 0.97) 0.46 (0.22, 1.00) 0.08
20-99 yr, Female 1.00 0.85 (0.58, 1.24) 0.78 (0.44, 1.36) 0.65 (0.31, 1.38) NS
Comparison of ethnicity; 20–99 yr, All (males and females combined)
Hispanic 1.00 0.56 (0.61, 0.96) 0.61 (0.32, 1.14) 0.37 (0.15, 0.91) 0.07
White 1.00 0.82 (0.63, 1.07) 0.64 (0.39, 1.05) 0.67 (0.34, 1.32) 0.11
Black 1.00 0.69 (0.41, 1.18) 1.17 (0.63, 2.19) 1.31 (0.49, 3.54) NS
Other 1.00 0.40 (0.11, 1.50) 0.27 (0.07, 0.97) 0.13 (0.01, 1.53) 0.05
Osteoporosis was determined as indicated if one or more of 2 conditions were satisfied: (1) Answer yes to question “Has a doctor ever told you that you had
osteoporosis, sometimes called thin or brittle bones?” and (2) Answer yes to question “Has a doctor ever told you that you had broken or fractured your hip?”.
ORs for osteoporosis were calculated for each quartile after adjustments for age, gender, kcal, BMI, intakes of calcium, protein, total dairy foods, and vitamin
D, and flags to denote supplemental calcium, supplemental vitamin D, supplemental multi vitamin/mineral and prescription medication for osteoporosis and
estrogen medication (females only).
aP trend values indicate statistically significantly different trends in 4 quartiles.
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osteoporosis in various ethnic groups, with a decreasing
trend in whites (OR=0.67; 95% CI, 0.34, 1.32; P = 0.11)
and Hispanics (OR=0.37; 95% CI, 0.15, 0.91; P = 0.07).
Other ethnic groups had a 87% lower risk of osteopor-
osis (P<0.05).
Several studies show that high P intake does not have a
negative impact on Ca balance. Spencer et al. [11] found
that an increase in P intake from 800 mg/day (the RDA)
to 2,000 mg/day in adult males failed to affect Ca balance
regardless of intake, which ranged from 200 to 2,000 mg/
day. Similarly, Heany and colleagues [12-15] reported that
intake of dietary P was inversely associated with both urin-
ary Ca excretion and intestinal Ca absorption, implying a
direct association with fecal Ca excretion. Changes in P in-
take by healthy adults affect Ca metabolism (i.e., decreased
intestinal Ca absorption and decreased renal excretion of
Ca). However, these outcomes most likely cancel each
other out, leaving Ca balance unaffected.
In several studies, a high ratio of P:Ca (approximately
3–4:1) in conjunction with low Ca intake led to adverse ef-
fects on bone health. Many of these reports had small
numbers of subjects or were of short duration. For ex-
ample, a cross-sectional study of 38 young females found
a negative association between P intake and radial bone
measurements [9]. Meaningful data interpretation was un-
likely with such a small sample. A cross-sectional observa-
tional study of 147 healthy females aged 31–43 years by
Kemi et al. [6,7] reported that with adequate Ca intake,the lowest quartile (Ca:P ratio of <0.51) had higher mean
serum parathyroid hormone (S-PTH) concentration (P =
0.021) and mean urinary Ca (U-Ca) excretion (P = 0.051)
than all other quartiles. It should be noted that the num-
ber of subjects in the study was too small for an observa-
tional study to make a reliable conclusion. Randomized
clinical trials have shown that the combination of high
P (1,500-1,700 mg) coupled with low Ca intake (375–
400 mg) increased serum PTH concentration in healthy
young females [4,5,8]. Portale et al. [10] found that a high
intake of P decreased the serum calcitriol concentration in
healthy males. It also acutely inhibited bone formation [4].
Kemi et al. [18] reported that when P intake was above
current recommendations, increased Ca intake was benefi-
cial for bone, as indicated by decreased S-PTH concentra-
tion and bone resorption; not even high Ca intake had
effect on bone formation when P intake was excessive. In
this study, 12 healthy female subjects aged 21–40 years
attended three 24-h study sessions. They were randomized
according to a Ca dose of 0 (control day), 600, or 1,200 mg,
and each subject served as her own control. The meals on
each study day provided 1,850 mg P and 480 mg Ca. Rising
Ca doses were accompanied by decreasing concentrations
of serum PTH (P < 0.001) and increasing serum ionized
Ca concentrations (P < 0.001), with no significant differ-
ences in the bone formation marker and serum bone-
specific alkaline phosphatase. It is worth noting that
the study duration of this study was too short to see a
meaningful impact on bone health parameters.
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IOM [3] stated that in balance studies, Ca:P molar ratios
of 0.08-2.4:1 (a 30 fold range) had no effect on either Ca
balance or absorption. The IOM also found that the in-
take ratio alone failed to take into account physiological
adaptive responses, such as bioavailability and renal out-
put. For example, in term-born infants during the first
year of life, a higher Ca content in soy-based formulas
reduced P absorption, but retention was similar due to
offsetting changes in renal P output. Thus, the IOM
concluded that there is little evidence for relating the
two nutrients.
Adequate dietary P is essential for building bone since
bone mineral is predominantly calcium phosphate [3].
Milk is the leading source of dietary P in the American
diet, but a synergistic effect of other nutrients in milk (e.g.,
calcium, protein, potassium, magnesium) may improve
absorption of dairy Ca [14]. Although Ca supplements
reduce its absorption compared to dairy milk [14], those
that contain P (e.g., tricalcium phosphate, dicalcium
phosphate) maintain strong bones and reduce the risk of
osteoporosis [15]. Our data show that high P intake is as-
sociated with high Ca intake as well as improved bone
health in some age/gender groups.
Other findings demonstrate beneficial effects of Ca
phosphate supplementation. Anabolic agents for treating
osteoporosis require positive P balances of up to 90 mg/
day [19]. A Ca phosphate supplement may be preferable
to carbonate or citrate salts because it preserves food P
[15]. Ditscheid et al. [20] reported that pentacalcium
hydroxy-triphosphate (Ca5(PO4)3OH) supplementation
provided additional daily intake of 1060 mg Ca and
490 mg P. These amounts significantly lowered serum
total and LDL cholesterol concentrations by 6.5% and
3.6%, respectively, after 4 weeks of supplementation.
This study has several shortcomings. First, its cross-
sectional design precludes the assignment of cause and ef-
fect. A prospective, longitudinal study may be more ap-
propriate for a population study. Second, lack of PTH data
in the NHANES dataset did not allow analysis of the
impact of high P intake on blood PTH concentrations.
Additional studies with parameters beyond bone health
should be considered before increasing P consumption.Conclusion
Our cross-sectional analyses of NHANES data show that
high P intake is associated with a 4.2% improvement in
BMC and a 2.1% improvement in BMD. It also reduced
risk of osteoporosis by 45% in adults whose Ca and P in-
takes were within normal ranges.Competing interests
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